Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
PaperCitations, authors & open-access status
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,219 citations, 2017 year and closed oa status.
1,219
Citations
2017
Year
closed
OA Status